bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 6765: A patient-derived hepatocellular carcinoma multicellular spheroid platform harnessing autologous patient serum to model the tumor microenvironment and treatment response
Authors: Crouchet Emilie , Almeida Nuno , Durand Sarah C. , Parnot Marie , Oudot Marine A. , Giannone Fabio , Gadenne Cloé , Cherradi Sara , Roehlen Natascha , Saviano Antonio , Felli Emanuele Emanuele , Pessaux Patrick , Chayama Kazuaki , Duong Hong Tuan F. , Baumert Thomas F. , Schuster Catherine 
Published: March 2024

Abstract
Hepatocellular carcinoma (HCC) is the third leading and fastest rising cause of cancer-related death worldwide. The discovery and preclinical development of compounds targeting HCC is hampered by the absence of authentic tractable systems recapitulating the heterogeneity of patient HCC tumors and the tumor microenvironment (TME). Here, we established a novel, simple and robust patient-derived multicellular tumorspheroid model based on clinical HCC tumor tissues combined with the autologous patient serum. The model was robust and reproducible independently from cancer etiology and grade recapitulating key functional features of original tissue. We show that the use of autologous patient serum was essential for the TME function. The tumorspheroids comprised the main cell compartments including epithelial cancer cells as well as all major cell populations of the TME (cancer-associated fibroblasts, macrophages and T cells). Cell type proportions were variable between tumorspheroids reflecting HCC heterogeneity. Moreover, we observed differential responses to FDA HCC approved drugs (including tyrosine kinase and checkpoint inhibitors as well as VEGF-targeting agents) between donors as in patients. This patient HCC serum-tumorspheroid model provides novel opportunities for drug discovery and development as well mechanism of action studies including compounds targeting the TME. In conclusion, this HCC serum-tumorspheroid platform will contribute to improve the dismal outcome of patients with HCC.
Citation Format: Emilie Crouchet, Nuno Almeida, Sarah C. Durand, Marie Parnot, Marine A. Oudot, Fabio Giannone, Cloé Gadenne, Sara Cherradi, Natascha Roehlen, Antonio Saviano, Emanuele Emanuele Felli, Patrick Pessaux, Kazuaki Chayama, Hong Tuan F. Duong, Thomas F. Baumert, Catherine Schuster. A patient-derived hepatocellular carcinoma multicellular spheroid platform harnessing autologous patient serum to model the tumor microenvironment and treatment response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6765.
Abstract 6770: Acquired temozolomide resistance instructs patterns of glioblastoma cell motility and proteome expression within gelatin hydrogels
Authors: Kriuchkovskaia Viktoriia , Eames Ela , Riggins Rebecca , Harley Brendan 
Published: March 2024

Abstract
Acquired drug resistance in glioblastoma (GBM) presents a major clinical challenge and is one of the key factors contributing to the abysmal prognosis with less than 15 months median overall survival. The aggressive chemotherapy with the frontline therapeutic, temozolomide (TMZ), ultimately fails to kill residual, highly invasive tumor cells after surgical resection and radiotherapy. Here, we present a robust three-dimensional (3D) in vitro hydrogel model of acquired temozolomide (TMZ) resistance using isogenically-matched glioblastoma (GBM) cell lines. We demonstrate distinct drug response patterns between TMZ-sensitive and TMZ-resistant GBM cells, emphasizing our model's promise for future pre-clinical investigations aimed at developing novel therapies targeting drug-resistant GBM. Importantly, our model detects apoptosis-related protein changes in response to TMZ, validating its ability to study drug-induced molecular changes. Furthermore, our study delves into the migratory potential of GBM cells within the 3D extracellular matrix environment. Additionally, we uncover significant alterations in cytokine expression associated with matrix remodeling and angiogenesis, providing new avenues for therapeutic investigation. Although our findings are derived from a specific set of isogenically-matched cell lines, this model highlights the potential to explore personalized treatment strategies. Ongoing research in our lab is dedicated to gaining a more profound understanding of matrix remodeling and the migratory potential of TMZ-resistant GBM cells. Moreover, our future work will aim to expand our study to include a wider range of cell lines and patient-derived xenografts within our advanced microphysiological systems that include key elements of GBM tumor microenvironment such as perivascular niche. This endeavor seeks to establish connections between observed therapeutic behaviors and clinical outcomes, ultimately contributing to the development of more effective treatments for GBM patients.
Citation Format: Viktoriia Kriuchkovskaia, Ela Eames, Rebecca Riggins, Brendan Harley. Acquired temozolomide resistance instructs patterns of glioblastoma cell motility and proteome expression within gelatin hydrogels [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6770.
Abstract 6775: 3D culture aggregation morphology depends on cell phenotype and gene expression profiles in lung cancer
Authors: Hayashi Naohiro , Tsudaka Shimpei , Suzawa Ken , Higashihara Tomoaki , Thu Yin Min , Matsuoka Atsushi , Mizuno Daisuke , Yoshichika Ryo , Mukohara Fumiaki , Yoshikawa Mao , Shien Kazuhiko , Yamamoto Hiromasa , Toyooka Shinichi 
Published: March 2024

Abstract
Background: Three-dimensional (3D) cell culture allows for the reproduction of tissue structure and function in a state more akin to the in vivo environment compared to two-dimensional (2D) cell culture. It is established that 3D culture more faithfully replicates cell morphology, differentiation, proliferation, gene and protein expression, and responsiveness to stimulation, as well as drug metabolism. Focusing on the observation that lung cancer cell lines exhibit different clustering morphologies in 3D cell culture, we conducted a comparative study on the relationship between these clustering morphologies and the characteristics of the lung cancer cell lines.
Methods: We cultured 30 lung cancer cell lines using 3D culture plate, and classified the types of cell clustering morphologies formed. We evaluated the molecular and cellular biology characteristics of all cell lines. Additionally, comprehensive gene expression analysis using RNA sequencing was performed on the 30 3D-cultured cell samples, and the characteristics of gene expression between different clustering types were compared.
Results: The 3D culture aggregation morphology of 30 lung cancer cell lines were classified into three types (monolayer sheet, NOS, spheroid). Monolayer sheet-type cells exhibited higher proliferation, migration, and invasion capabilities compared to spheroid-type cells. In the transcriptomic bioinformatics analysis of the acquired gene expression data, GSEA analysis using Hallmark gene sets showed that the enrichment of epithelial-mesenchymal transition (EMT) and cancer metastasis-related genes in the monolayer type cells significantly compared to the spheroid type cells. Conversely, cell adhesion and intercellular binding-related gene sets were highly enriched in the spheroid type cells.
Conclusion: 3D culture aggregation morphology represents phenotypic properties and transcriptomic profiles in non-small cell lung cancer cells.
Citation Format: Naohiro Hayashi, Shimpei Tsudaka, Ken Suzawa, Tomoaki Higashihara, Yin Min Thu, Atsushi Matsuoka, Daisuke Mizuno, Ryo Yoshichika, Fumiaki Mukohara, Mao Yoshikawa, Kazuhiko Shien, Hiromasa Yamamoto, Shinichi Toyooka. 3D culture aggregation morphology depends on cell phenotype and gene expression profiles in lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6775.
Abstract 6777: An ex-vivo organotypic culture platform of mucinous carcinomatosis peritonei identifies CDK4-6 inhibition as a novel treatment
Authors: Weitz Jonathan , Nishizaki Daisuke , Patel Jay , Ng Isabella , Sun Siming , Ramms Dana , Zou Jingjing , Baumgartner Joel , Kelly Kaitlyn , Patel Hitendra , White Rebekah , Veerapong Jula , Vu Peter , Gutkind Silvio , Tiriac Herve , Kato Shumei , Lowy Andrew 
Published: March 2024

Abstract
Concomitant mutations in KRAS and GNAS have been linked to mucinous histology in gastrointestinal neoplasms of the appendix, colon, and pancreas (IPMN). Upon progression, these tumors are characterized by metastasis which favors the peritoneal surface, resulting in mucinous carcinomatosis peritonei (MCP). Recently we have described a novel technique which allows for long term culture and drug intervention of human MCP tumors ex-vivo. With evidence of durable clinical benefit of CDK4-6 inhibition in a single patient with chemo refractory MCP of appendiceal origin, we sought to further investigate anti-tumor responses using CDK4-6 inhibition in ex-vivo tumor slices, in order to identify candidates for a personalized clinical therapy trial. Here, in a comparison of ex-vivo patient tumor slices from 18 individual donors, treatment using CDK4-6 inhibitors revealed a significant reduction in cancer cell specific proliferation in mucinous GNAS-mut tumors compared to non-mucinous cancers. Anti-tumor responses of CDK4-6 were determined to be tumor-cell intrinsic, as CDK4-6 inhibition blocked proliferation of stromal cells in the TME independently of patient tumor mutational and mucin status. Based on these finding a personalized clinical trial was conducted where we report that 13 of 16 patients (81%) enrolled with MCP treated with palbociclib had at least a 10% decrease in CEA, as compared to historical chemotherapy responses rates reported from 14-30%. These results indicate that CDK4/6 inhibition is a novel and efficacious treatment for patients with MCP.
Citation Format: Jonathan Weitz, Daisuke Nishizaki, Jay Patel, Isabella Ng, Siming Sun, Dana Ramms, Jingjing Zou, Joel Baumgartner, Kaitlyn Kelly, Hitendra Patel, Rebekah White, Jula Veerapong, Peter Vu, Silvio Gutkind, Herve Tiriac, Shumei Kato, Andrew Lowy. An ex-vivo organotypic culture platform of mucinous carcinomatosis peritonei identifies CDK4-6 inhibition as a novel treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6777.
Abstract 6824: Secretion of MAGE-A3 and MAGE-A4 in cell lines and lung cancer
Authors: Gilmore Bailey , Kong Dehe , Gonzalez Rachel , Yom Jina , Han Andy , Qu Tianli , Strom Alex , Zhao Xiaoxiao , Zewdu Eden , Guo Hailey , Guo Zhaoying , Zhang Ranran , Hu Xiaomin , Ren Qi , Liu Xuan , Fu Wei 
Published: March 2024

Abstract
Melanoma-associated antigen gene A (MAGE-A) family of proteins have previously been shown to express in a variety of tumors, having different roles in cancer pathogenesis. MAGE-A3 and MAGE-A4 have both been shown to inhibit the p53 pathway which leads increased cell growth by stopping apoptosis. Both of these proteins have been associated with cancer progression and poor prognosis. In our studies, we have evaluated multiple MAGE-A3 and MAGE-A4 antibodies using CytoSections. While previous research had only pointed to these proteins being intracellular, our overexpression studies in the development of CytoSections indicated that some MAGE-A proteins were secreted. In this study, ELISA binding assays corroborated that MAGE-A3 and MAGE-A4 were secreted from cells overexpressing these proteins, and serum MAGE-A4 was detected in 24% of lung cancer patients. Flow cytometry data was then collected to see that exogenous MAGE-A proteins were binding to cells in a pattern consistent with secretion data from IHC experiments. Variants of MAGE-A4, differing by only a handful of amino acids, showed very different levels of secretion from one another. MAGE-A3 and MAGE-A6 share 95% homology and were also extremely different in secretion shown between IHC, flow cytometry, and ELISA. This study validates that certain members of the MAGE-A family are secreted from cells.
Citation Format: Bailey Gilmore, Dehe Kong, Rachel Gonzalez, Jina Yom, Andy Han, Tianli Qu, Alex Strom, Xiaoxiao Zhao, Eden Zewdu, Hailey Guo, Zhaoying Guo, Ranran Zhang, Xiaomin Hu, Qi Ren, Xuan Liu, Wei Fu. Secretion of MAGE-A3 and MAGE-A4 in cell lines and lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6824.
Abstract 6872: A spatio-temporal approach to mapping the dynamics of cutaneous squamous cell carcinoma progression and immunotherapy response: A journey through TiME
Authors: Jhaveri Niyati , Ben Cheikh Bassem , Klymyshyn Dmytro , Ma Ning , Pratapa Aditya , Monkman James , Nelson Nadine , Kulasinghe Arutha 
Published: March 2024

Abstract
Background: Cutaneous squamous cell carcinoma (cSCC), arising from proliferation of malignant epidermal keratinocytes, is the second most common non-melanoma skin cancer. cSCC accounts for 75% of all skin cancer related deaths excluding melanoma, and metastatic and immunotherapy-resistant cases pose an emerging global threat. Tumor development is a gradual process characterized by high mutational burden and an immunosuppressive tumor immune microenvironment (TiME); therefore, identifying the underlying changes across the spatial and temporal landscape of these tumors will be crucial to understanding the key cellular and molecular drivers of disease progression and response.
Methods: In this longitudinal study, we used a single-cell, whole-slide approach to mapping key proteins of immune lineage, tissue architecture, cellular metabolism, and stress to study the spatial landscape of cSCC at baseline (pre-treatment) and multiple time points over the course of immunotherapy with the aim to develop a temporal atlas of the tumor. An ultra-high plex antibody panel encompassing over 50 major determinants in the tumor microenvironment was employed on the PhenoCycler®-Fusion spatial biology platform. Deep bioinformatic analyses was performed to identify cellular phenotypes, spatial neighborhoods, heterogenous functional states and cellular interactions by spatial proximity determinations.
Results: Previous studies in our laboratory have identified unique phenotypes correlating with response and resistance to immunotherapies in pre-treatment cSCC biopsies. Our results expand on these findings with temporal data tracking the dynamic changes in the TiME over the course of immune checkpoint inhibitor therapy. Apart from differences in immune cell composition and spatial localization patterns, we also saw differences in macrophage polarization and expression of metabolic markers in the responder and non-responder cohorts.
Conclusions: Overall, ultrahigh-plex spatio-temporal monitoring of cSCC revealed distinct signatures of response and resistance and identified key features in the TiME that reveal deeper insights into the pathobiology of the tumor. Our discovery-based approach identifies novel biomarkers for patient stratification and therapeutic modulation.
Citation Format: Niyati Jhaveri, Bassem Ben Cheikh, Dmytro Klymyshyn, Ning Ma, Aditya Pratapa, James Monkman, Nadine Nelson, Arutha Kulasinghe. A spatio-temporal approach to mapping the dynamics of cutaneous squamous cell carcinoma progression and immunotherapy response: A journey through TiME [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6872.
Abstract 6903: Treatment efficacy of transcatheter hepatic arterial infusion chemotherapy with cisplatin in a severe immunodeficient rat model with patient-derived primary pancreatic ductal adenocarcinoma xenografted into the liver
Authors: Kageyama Ken , Yamamoto Akira , Ozaki Masanori , Kimura Kenjiro , Eguchi Shinpei , Tanaka Ryota , Terai Mizue , Sato Takami , Miki Yukio 
Published: March 2024

Abstract
Purpose: Liver metastases of pancreatic ductal adenocarcinoma (PDAC) is a highly fatal disease; most patients die within 5 years. There is a critical need to identify appropriate anticancer treatments for these patients. A patient-derived tumor xenograft (PDX) model in severe immunodeficient rat with primary PDAC xenografted into the liver is suitable for evaluating transcatheter hepatic arterial infusion chemotherapy.
Materials and Methods: The purpose of this study was to develop a severe immunodeficient rat model with patient-derived primary PDAC xenografted into the liver, and to assess the treatment efficacy of hepatic arterial infusion chemotherapy with cisplatin in this model. Three patient-derived tumors of PDAC were transplanted into the liver of 21 rats each, totaling 63 rats. Four weeks after transplantation, the 21 rats were randomly assigned into three treatment groups of seven rats each: hepatic arterial infusion, systemic venous infusion, and control group. Tumor volumes were evaluated on CT twice at pre-treatment and 4-weeks post-treatment. Following euthanasia of the rats, resected tumor specimens were pathologically analyzed.
Results: The liver-implanted PDAC PDX rat model was established in all 63 rats. hepatic arterial infusion chemotherapy and systemic venous infusion chemotherapy with cisplatin were able to be performed in the assigned rats. The hepatic arterial infusion group significantly inhibited tumor growth and reduced Ki67 expression, indicating lower cell proliferation, compared to the control group in three PDX tumors.
Conclusion: A rat-based preclinical platform was established by liver-implanted PDAC PDX rat model. Arterial cisplatin infusion chemotherapy would be one of potential therapies for PDAC liver metastases.
Citation Format: Ken Kageyama, Akira Yamamoto, Masanori Ozaki, Kenjiro Kimura, Shinpei Eguchi, Ryota Tanaka, Mizue Terai, Takami Sato, Yukio Miki. Treatment efficacy of transcatheter hepatic arterial infusion chemotherapy with cisplatin in a severe immunodeficient rat model with patient-derived primary pancreatic ductal adenocarcinoma xenografted into the liver [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6903.
Abstract 6906: Engineered bacteria launch and control an oncolytic virus
Authors: Pabon Jonathan , Singer Zakary , Huang Hsinyen , Rice Charles , Danino Tal 
Published: March 2024

Abstract
The ability of bacteria and viruses to selectively replicate in tumors has led to synthetic engineering of new microbial therapies. In our system, Salmonella has been programmed to produce Senecavirus A (SVA)-RNA and launch an SVA infection in bacterially-infected cancer cells. Utilizing time-lapse microscopy, we visualize S. typhimurium invasions into cancer cells and their subsequent delivery of multiple picornaviral species. S.-typhimurium-viral-RNA launch in vitro identified a small-cell-lung cancer cell line, H446, as a promising candidate for S.-typhimurium-SVA launch. This viral RNA-carrying Salmonella strain confers complete tumor regression in vivo. Finally, we integrate into this strain a protease-dependent mechanism to confer SVA-infection spatial localization. This work, to the best of our knowledge, is the first instance of bacteria delivering full-length viral RNAs for therapeutic oncolytic purposes.
Citation Format: Jonathan Pabon, Zakary Singer, Hsinyen Huang, Charles Rice, Tal Danino. Engineered bacteria launch and control an oncolytic virus [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6906.
Abstract 6918: Ba/F3-BCR-ABL engineering cell line panel, a useful platform for novel drug discovery
Authors: Wang Guoqian , Peng Yao , Wang Yu , Tang Yao , Xu Jingxiao , Ning Jinying , Hao Feng 
Published: March 2024

Abstract
In the past few years, with the great success of Imatinib, the first kinase inhibitor, Imatinib rapidly became the first-line treatment for CML (Chronic myelogenous leukemia) carrying the BCR-ABL mutation. It opened a new chapter in targeted cancer treatment. Despite the increase in overall survival allowed by imatinib, the onset of drug resistance led scientists to investigate imatinib's fine structural mechanism of action to develop new and more effective compounds against mutated forms of Bcr-Abl. 7 BCR-ABL inhibitors have been approved, they are Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib, Olverembatinib, and Asciminib. However, acquired resistance has been a major challenge in the treatment of CML, and some patients still experience disease progression or even death due to drug resistance. BCR-ABL kinase domain mutations are one of the important mechanisms of acquired resistance, with the T315I mutation being the most common type of drug resistance mutation, accounting for approximately 25% of drug-resistant CML cases. Patients with T315I mutations in CML are resistant to all current first- and second-generation BCR-ABL inhibitors. Asciminib is designed as an allosteric inhibitor combined with an ATP-competitive TKI agent, which may hinder the development of mutation-driven acquired resistance or restore efficacy against highly resistant BCR-ABL mutants. Our group has generated 38 Ba/F3-BCR-ABL engineering cell lines as useful models for novel drug discovery in vitro and in vivo, including wild-type BCR-ABL and inhibitors leading drug resistance mutations, such as T315I, E255, Y253, F317, F359. V299, G250, A337T, V468F, and double mutations. Each cell was validated by cell sequencing and cell efficacy verification using approved BCR-ABL inhibitors. The Ba/F3-BCR-ABL engineering cell line panel can be useful for developing and evaluating next-generation BCR-ABL inhibitors and exploring newly acquired resistance mutations in BCR-ABL.
Citation Format: Guoqian Wang, Yao Peng, Yu Wang, Yao Tang, Jingxiao Xu, Jinying Ning, Feng Hao. Ba/F3-BCR-ABL engineering cell line panel, a useful platform for novel drug discovery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6918.